Posted by Michael Wonder on 20 Jun 2023
Cemiplimab for the treatment of patients with recurrent or metastatic cervical cancer
20 June 2023 - NICE is unable to make a recommendation on the use of cemiplimab (Libtayo) for the treatment of adults with recurrent or metastatic cervical cancer because Sanofi did not provide an evidence submission.
NICE will review this decision if Sanofi decides to make a submission.
